VIVUS, Inc. Logo

Email this page: News Release

VIVUS and Selten Pharma Announce Agreement for the Development and Commercialization Rights to Treatments for Pulmonary Arterial Hypertension (PAH)

 

Separate multiple addresses with commas. Maximum 200 characters.
 
 


These email addresses will be used to email the page on your behalf and will not be used by VIVUS, Inc. for any marketing purposes.

Send:       


 
This helps VIVUS, Inc. prevent automated submissions.